- Advanced search
- Immuno Portal
- Malaria Portal
|Approved drug?||Yes (FDA FDA (1997), EMA (1999))|
|International Nonproprietary Names|
|L04AC01 | RO-24-7375 | Ro-247375 | Zenapax®|
|Daclizumab is a monoclonal antibody binding to the α subunit (CD25) of the high-affinity interleukin-2 receptor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
An advanced version of daclizumab, with identical primary sequence, but which is differentially gylcosylated, called daclizumab beta (BIIB019, DAC HYP) has been developed for subcutaneous administration. Daclizumab beta's alternate glycosylation pattern changes its binding to Fc receptors and reduces its propensity to induce complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
|GtoPdb PubChem SID||178103462|
|Search PubMed clinical trials||daclizumab|
|Search PubMed titles||daclizumab|
|Search PubMed titles/abstracts||daclizumab|